Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Natàlia Vilor‐Tejedor, Alyssa Stevensson et al.|JAMA Neurology|2021Cited by 627
A multicentre validation study of the diagnostic value of plasma neurofilament lightNicholas J. Ashton, Oskar Hansson, Shorena Janelidze et al.|Nature Communications|2021Cited by 554
Biomarker modeling of Alzheimer’s disease using PET-based Braak stagingJoseph Therriault, Pedro Rosa‐Neto, Tharick A. Pascoal et al.|Nature Aging|2022Cited by 300
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Pedro Rosa‐Neto, Marie Vermeiren et al.|JAMA Neurology|2022Cited by 261
Biomarker-based staging of Alzheimer disease: rationale and clinical applicationsJoseph Therriault, Pedro Rosa‐Neto, Suzanne E. Schindler et al.|Nature Reviews Neurology|2024Cited by 171